BioNTech SE Sponsored ADR BNTX
98.52
(0.74)
(0.75%)
as of 25 Sep
- Market cap
- $24.9B
- P/E
- 0.0×
Follow BNTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.68 | 7.09 | 7.05 | 7.81 | |
P/FCF ratio |
0.00 | 0.00 | 39.95 | 47.08 | |
P/Operating CF |
26.47 | 66.76 | (45.68) | 1,525.76 | |
P/B ratio |
1.09 | 1.06 | 1.03 | 1.14 | |
Price to Tangible BV |
1.21 | 1.18 | 1.15 | 1.27 | |
EV/Sales |
1.95 | 2.00 | 1.80 | 2.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(20.16) | 12.56 | 6.78 | 8.91 | |
EV/FCF |
(5.60) | (19.85) | 10.17 | 13.49 | |
Quick Ratio |
6.89 | 7.40 | 8.64 | 7.70 | |
Current Ratio |
7.12 | 7.54 | 8.80 | 7.85 | |
Net Debt/EBITDA |
(178.52) | 73.50 | 25.78 | 21.18 | |
Debt/Assets |
1.15% | 1.22% | 1.44% | 1.55% | |
Debt/Equity |
0.01 | 0.01 | 0.02 | 0.02 | |
Asset Turnover |
0.14 | 0.13 | 0.14 | 0.13 | |
Operating CF/Net income |
(26.56) | (0.92) | 0.79 | (0.02) | |
Capex/Depreciation |
(0.43) | (0.25) | (0.64) | (0.19) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
37.18% | 59.99% | 471.63% | 521.78% | |
Selling, General and Administrative Expense of Revenue |
9.78% | 25.42% | 127.69% | 187.31% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
1.63% | 1.84% | 17.53% | 7.35% | |
Graham Net Nets |
0.64 | 0.66 | 0.68 | 0.63 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.67%) | (5.50%) | (6.62%) | (8.41%) | |
Free Cash Flow Yield |
(5.22%) | (1.42%) | 2.50% | 2.12% | |
Revenue per Share |
7.42 | 4.07 | 0.55 | 0.48 | |
Operating CF per Share |
3.73 | 1.43 | (1.95) | 0.06 | |
Capex per Share |
(0.27) | (0.18) | (0.36) | (0.24) | |
Free Cash Flow per Share |
3.46 | 1.24 | (2.30) | (0.18) | |
Cash per Share |
71.00 | 69.64 | 67.65 | 67.83 | |
Shareholders Equity per Share |
90.31 | 89.99 | 86.41 | 81.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
90.31 | 89.99 | 86.41 | 81.50 | |
Free Cash Flow |
827.64 | 300.71 | (583.21) | (44.42) | |
Working Capital |
15,906.63 | 15,844.46 | 16,112.66 | 15,519.84 | |
Capital Expenditures |
(63.54) | (43.97) | (90.47) | (59.87) | |
Net Current Asset Value |
15,157.01 | 15,140.62 | 15,397.20 | 14,780.47 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.65 | 0.49 | |
Net Profit Margin |
(1.89%) | (38.14%) | (450.38%) | (777.27%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,111.96 | 1,371.67 | 888.76 | 952.71 | |
Average Payables |
652.94 | 533.46 | 508.11 | 662.14 | |
Average Inventory |
298.55 | 215.90 | 194.75 | 189.43 | |
Average Assets |
24,788.99 | 24,628.65 | 23,490.40 | 24,107.67 | |
Average Common Equity |
21,308.22 | 21,377.51 | 20,911.54 | 20,826.82 |
Columns are period end dates